Patent application number | Description | Published |
20080312471 | Polymorphs of atomoxetine hydrochloride - The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder. | 12-18-2008 |
20090030207 | Polymorphs of Dolasetron base and process for preparation thereof - The present invention provides polymorphic forms of dolasetron base and methods for their use and preparation. | 01-29-2009 |
20090062546 | Dolasetron trifluoroacetate, polymorphs of dolasetron trifluoroacetate and process for preparation thereof - Provided are crystalline forms of dolasetron trifluoroacetate, methods for their preparation, and their use in preparing dolasetron mesylate. | 03-05-2009 |
20090137821 | Method of making dorzolamide hydrochloride - Processes for the preparation of dorzolamide hydrochloride and an intermediate of Formula IV, | 05-28-2009 |
20100076225 | Polymorphs of atomoxetine hydrochloride - The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder. | 03-25-2010 |
20100130458 | Polymorphs of fluticasone furoate and process for preparation thereof - Provided are polymorphs of fluticasone furoate and processes for preparation thereof. | 05-27-2010 |
20100216831 | DESLORATADINE CRYSTALLINE FORMS MIXTURES HAVING A LOW LEVEL OF RESIDUAL SOLVENTS - Provided are desloratadine mixtures, comprising a low level of residual solvents and processes for the preparation thereof. | 08-26-2010 |
20100240629 | POLYMORPHS OF FLUTICASONE FUROATE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides crystalline forms of Fluticasone furoate, characterized by the data disclosed in the specification; pharmaceutical compositions comprising any one or combination of the crystalline forms of Fluticasone furoate and at least one pharmaceutically acceptable excipient; and the use of the crystalline forms of Fluticasone furoate in the preparation of pharmaceutical formulations. | 09-23-2010 |
20130303472 | SOLID STATE FORMS OF FIDAXOMYCIN AND PROCESSES FOR PREPARATION THEREOF - The present invention provides solid state forms of Fidaxomycin, processes for preparing the solid state forms, as well as pharmaceutical compositions and formulations comprising one or more of the solid state forms of Fidaxomycin, and processes for the preparation of the compositions and formulations. The solid state forms of the present invention exhibit advantageous properties such as improved reliability and reproducibility in manufacturing and processing and stability in formulations. | 11-14-2013 |
20140128334 | Solid State Forms Of Fidaxomycin And Processes For Preparation Thereof - The present invention provides solid state forms of Fidaxomycin, processes for preparing the solid state forms, as well as pharmaceutical compositions and formulations comprising one or more of the solid state forms of Fidaxomycin, and processes for the preparation of the compositions and formulations. The solid state forms of the present invention exhibit advantageous properties such as improved reliability and reproducibility in manufacturing and processing and stability in formulations. | 05-08-2014 |